The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Alnylam Unveils Positive Cardiovascular Data for RNAi Portfolio at ACC.26

Key Facts

1Alnylam presented new clinical data supporting the efficacy of Vutrisiran in treating ATTR-CM (transthyretin amyloidosis with cardiomyopathy).

2Data demonstrated the potential of Zilebesiran for the management of hypertension.

3The results were presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

Create Free Account

Version History

1 additional source confirmed this story

Alnylam Pharmaceuticals (Nasdaq: ALNY) presented new clinical and real-world data at the American College of Cardiology's Annual Scientific Session (ACC.26). The findings reinforce the therapeutic potential of the company's RNAi portfolio, specifically highlighting the efficacy of Vutrisiran in treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Additionally, data demonstrated the potential of Zilebesiran as a long-term management solution for hypertension. These presentations aim to provide robust clinical evidence for the durability and effectiveness of RNAi therapeutics in managing complex cardiovascular conditions. Positive clinical results for key pipeline assets are expected to strengthen investor confidence in Alnylam's commercial prospects and R&D capabilities. The company continues to position itself as a leader in the development of innovative genetic medicines for high-need patient populations.